                         SEQUENCE LISTING

<110>  President and Fellows of Harvard College
 
<120>  SYSTEMS AND METHODS INVOLVING INTERACTIONS SUCH AS PROTEIN OR 
       VIRUS INTERACTIONS

<130>  H0498.70495WO00

<140>  Not Yet Assigned
<141>  2015-01-09

<150>  US 61/926,179
<151>  2014-01-10

<160>  8     

<170>  PatentIn version 3.5

<210>  1
<211>  35
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  1

Gly Gly Gly Ser Gly Gly Gly Gly Gln Phe Gly Leu Thr Val Val Gly 
1               5                   10                  15      


Val Val Gly Gly Leu Leu Gly Ser Leu Val Leu Leu Val Trp Val Leu 
            20                  25                  30          


Ala Val Ile 
        35  


<210>  2
<211>  35
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  2

Gly Gly Gly Ser Gly Gly Gly Ser Asp Asn Thr Asn Ser Arg Val Val 
1               5                   10                  15      


Leu Trp Ser Phe Phe Glu Ala Leu Val Leu Val Ala Met Thr Leu Gly 
            20                  25                  30          


Gln Ile Tyr 
        35  


<210>  3
<211>  35
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide

<400>  3

Gly Gly Gly Ser Gly Gly Gly Ser Glu Ser Thr Asn Thr Arg Val Leu 
1               5                   10                  15      


Tyr Phe Ser Ile Phe Ser Met Phe Cys Leu Ile Gly Leu Ala Thr Trp 
            20                  25                  30          


Gln Val Phe 
        35  


<210>  4
<211>  35
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  GFP-tagged

<400>  4

Gly Gly Gly Ser Gly Gly Gly Ser Glu Ser Thr Asn Thr Arg Val Leu 
1               5                   10                  15      


Tyr Phe Ser Ile Phe Ser Met Phe Cys Leu Ile Gly Leu Ala Thr Trp 
            20                  25                  30          


Gln Val Phe 
        35  


<210>  5
<211>  35
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  GFP-tagged

<400>  5

Gly Gly Gly Ser Gly Gly Gly Ser Asp Asn Thr Asn Ser Arg Val Val 
1               5                   10                  15      


Leu Trp Ser Phe Phe Glu Ala Leu Val Leu Val Ala Met Thr Leu Gly 
            20                  25                  30          


Gln Ile Tyr 
        35  


<210>  6
<211>  35
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  GFP-tagged

<400>  6

Gly Gly Gly Ser Gly Gly Gly Pro Gln Asp Arg Leu Arg Ala Leu Val 
1               5                   10                  15      


Val Ile Pro Ile Ile Phe Gly Ile Leu Phe Ala Ile Leu Leu Val Leu 
            20                  25                  30          


Val Phe Ile 
        35  


<210>  7
<211>  35
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  GFP-tagged

<400>  7

Gly Gly Gly Ser Gly Gly Gly Thr Ser Tyr Asn Ser Lys Ala Leu Ile 
1               5                   10                  15      


Ala Phe Leu Ala Phe Leu Ile Ile Val Thr Ser Ile Ala Leu Leu Val 
            20                  25                  30          


Val Leu Tyr 
        35  


<210>  8
<211>  35
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Polypeptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  GFP-tagged

<400>  8

Gly Gly Gly Ser Gly Gly Gly Gly Gln Phe Gln Thr Leu Val Val Gly 
1               5                   10                  15      


Val Val Gly Gly Leu Leu Gly Ser Leu Val Leu Leu Val Trp Val Leu 
            20                  25                  30          


Ala Val Ile 
        35  


